|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
648200330[A34050281]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2016.08.01)(ÇöÀç¾à°¡)
\107 ¿ø/1Á¤(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öÀÇ ¿øÇüÁ¤Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
60, 120, 500, 1000Á¤ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 50¸¶ÀÌÅ©·Î±×·¥ |
500 Á¤ |
º´ |
8806482003308 |
8806482003322 |
|
| 50¸¶ÀÌÅ©·Î±×·¥ |
200 Á¤ |
º´ |
8806482003308 |
8806482003315 |
|
|
| ÁÖ¼ººÐÄÚµå |
218302ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ ÁúȯÀÇ ±âµµÆó¼â¼º Àå¾Ö¿¡ ÀÇÇÑ È£Èí°ï¶õ µî ¿©·¯ Áõ»óÀÇ ¿ÏÈ :
±â°üÁöõ½Ä, ±Þ¡¤¸¸¼º±â°üÁö¿°, Æó±âÁ¾
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
(°æ±¸ : Á¤Á¦)
o ¼ºÀÎ : ÇÁ·ÎÄ«Å×·Ñ¿°»ê¿°¼öȹ°·Î¼ 1ȸ 50¥ìg 1ÀÏ 1ȸ(Ãëħ½Ã) ¶Ç´Â 1ÀÏ 2ȸ(¾ÆÄ§, Ãëħ½Ã) °æ±¸Åõ¿©ÇÑ´Ù.
o ¼Ò¾Æ(6¼¼ ÀÌ»ó) : 1ȸ 25¥ìg 1ÀÏ 1ȸ(Ãëħ½Ã) ¶Ç´Â 1ÀÏ 2ȸ(¾ÆÄ§, Ãëħ½Ã) Åõ¿©ÇÑ´Ù(25¥ìg Á¦Á¦¿¡ ÇÑÇÔ).
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
ºñÈļº ½É±Ùº´Áõ ȯÀÚ |
| ½ÅÁßÅõ¿© |
1) °©»ó¼±±â´ÉÇ×ÁøÁõ ȯÀÚ
2) °íÇ÷¾Ð ȯÀÚ
3) ½ÉºÎÀüÁõ, ºÎÁ¤¸Æ µî ½ÉÁúȯ ȯÀÚ
4) ´ç´¢º´ ȯÀÚ
5) ±³°¨½Å°æÈïºÐ¼º ¾Æ¹Î·ù¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
6) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ |
| ÀÌ»ó¹ÝÀÀ |
1) Á¤½Å½Å°æ°è : ¶§¶§·Î µÎÅë, ¼öÁöÁøÀü, Á¹À½, À̸í, µå¹°°Ô ¾îÁö·¯¿ò, ½Å°æ°ú¹Î, ºÒ ¸é, ¼öÁö°æÃà µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ¼øÈ¯±â°è : ¶§¶§·Î ½É°èÇ×Áø, ºó¸Æ, Ç÷¾Ðº¯µ¿, µå¹°°Ô ºÎÁ¤¸Æ, °íÇ÷¾Ð, Çù½ÉÁõ µî ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼Òȱâ°è : ¶§¶§·Î ½Ä¿åºÎÁø, ¼ÒȺҷ®, ±¸¿ª, ±¸Åä, À§ºÎºÒÄè°¨ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) È£Èí±â°è : µå¹°°Ô ±âħ, ±â°üÁö¿°, õ¸í, ¸Å¿ì µå¹°°Ô Àεο°, ºñÃæÇ÷ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) °ú¹ÎÁõ : µå¹°°Ô ÇǺιßÁø, ¸Å¿ì µå¹°°Ô Ç÷°üºÎÁ¾, µÎµå·¯±â, ±â°üÁö°æ·Ã, ±¸°ÀεκÎÁ¾, ÀúÇ÷¾Ð, ÇãÅ» µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
6) ±âŸ : µå¹°°Ô ±¸°¥, ±¸³»¿°, ¾È¸éÈ«Á¶, Àü½Å±Çۨ, ¿°¨, ÄÚ¸·Èû µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ÀÌ ¾àÀ» ¿¡Çdz×ÇÁ¸°, À̼ÒÇÁ·ÎÅ×·¹³î µîÀÇ Ä«Å×Äݾƹηù¿Í º´¿ëÇÏ¸é ºÎÁ¤¸Æ ¶Ç´Â ½ÉÁ¤Áö¸¦ ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
2) MAOÀúÇØÁ¦³ª »ïȯ°è Ç׿ì¿ïÁ¦·Î Ä¡·áÁßÀΠȯÀÚ¿¡°Ô ÀÌ ¾àÀ» Åõ¿©Çϸé ÀÌ ¾àÀÇ Ç÷°ü°è¿¡ ´ëÇÑ ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖÀ¸¹Ç·Î ƯÈ÷ ÁÖÀÇÇÑ´Ù.
3) ÀÌ ¾àÀ» ÇÁ·ÎÇÁ¶ó³î·Ñ µîÀÇ ºñ¼±ÅÃÀû ¥â-Â÷´ÜÁ¦¿Í º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
4) ´Ù·®ÀÇ ´Ù¸¥ ±³°¨½Å°æÈïºÐÁ¦¸¦ Åõ¿©¹Þ°í Àִ ȯÀÚ¿¡°Ô ÀÌ ¾àÀ» Åõ¿©½Ã¿¡´Â ÁÖ ÀÇÇÑ´Ù. |
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Procaterol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.
|
| Pharmacology |
Procaterol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Procaterol is a long-acting beta-2-adrenergic receptor agonist. It is a potent bronchodilator that may be administered orally or by aerosol inhalation.
|
| Half-life |
Procaterol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Procaterol¿¡ ´ëÇÑ Absorption Á¤º¸ Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses.
|
| Pharmacokinetics |
Procaterol HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : ÈíÀԽà : 5ºÐ. °æ±¸ : 30ºÐ
- ÀÛ¿ëÁö¼Ó½Ã°£ : ÈíÀÔ, °æ±¸ : 8-12½Ã°£ (¿ë·®ÀÇÁ¸Àû)
- Èí¼ö : À§Àå°üÀ¸·Î Àß Èí¼öµÊ
|
| Biotransformation |
Procaterol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Procaterol¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor.
|
| Drug Interactions |
Procaterol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Procaterol¿¡ ´ëÇÑ Description Á¤º¸ A long-acting beta-2-adrenergic receptor agonist. It is a potent bronchodilator that may be administered orally or by aerosol inhalation. [PubChem]
|
| Drug Category |
Procaterol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic beta-AgonistsBronchodilator AgentsSympathomimetics
|
| Smiles String Canonical |
Procaterol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCC(NC(C)C)C(O)C1=C2C=CC(=O)NC2=C(O)C=C1
|
| Smiles String Isomeric |
Procaterol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC[C@H](NC(C)C)[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
|
| InChI Identifier |
Procaterol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H22N2O3/c1-4-12(17-9(2)3)16(21)11-5-7-13(19)15-10(11)6-8-14(20)18-15/h5-9,12,16-17,19,21H,4H2,1-3H3,(H,18,20)/t12-,16+/m0/s1/f/h18H
|
| Chemical IUPAC Name |
Procaterol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 8-hydroxy-5-[(1R,2S)-1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|